Literature DB >> 8597745

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.

K E Anderson, A C Girdwood, J A Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8597745      PMCID： PMC2350517          DOI： 10.1136/bmj.312.7032.702

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

1.  Selegiline in Parkinson's disease.

Authors:  D B Calne
Journal:  BMJ       Date:  1995-12-16

2.  Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.

Authors:  F Baronti; T L Davis; R C Boldry; M M Mouradian; T N Chase
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910
  2 in total
  2 in total

1.  Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.

Authors:  A Churchyard; C J Mathias; P Boonkongchuen; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

2.  Mortality associated with selegiline in Parkinson's disease. What do the available data mean?

Authors:  Y Mizuno; T Kondo
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.228
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.